ReWalk Robotics plans India launch of walking device by second quarter http://t.co/8MiKgqyGOJ
— Reuters India (@ReutersIndia) March 27, 2015
The above article does a great job summarizing the current state of ReWalk and the importance this development could have on the company’s financial performance. ReWalk’s stock has been continually sliding from a 52-week high of $43.71 down to the $13 dollar range. Part of this slump is most likely due to the realization by investors that exoskeleton technology companies are still a long way from achieving large sales volumes. For example, the ReWalk exoskeleton is the only product approved for home use by the FDA, however, the exoskeleton is still slow, unstable, and requires a certified person to be always present to assist with its operation (for more information see Overselling the Dream of Personal Use Exoskeletons). This combined with the high cost of the device means that for now, the average consumer with mobility impairment will choose a wheelchair over a power suit. Arguably, five or ten years from now this will no longer be the case, but investors looking to make a quick profit from ReWalk will continue fleeing the company.